TQB3616
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQB3616 is one of 91 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
2
Indications
12
Total Trials
6
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1TQB3616
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer6 trials
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05365178·432 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05365178·432 enrolledShow 3 more trials
TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05375461·287 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05375461·287 enrolled2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQB3616. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details